Gene · 7307
Papers3,382
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
841 to 860 of 3,382
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia. | Blood Cancer J | 2022 | 35973983 | PubTator, text mining | PubMed |
| Correlation Analysis and Prognostic Impacts of Biological Characteristics in Elderly Patients with Acute Myeloid Leukemia. | Clin Interv Aging | 2022 | 35967966 | PubTator, text mining | PubMed |
| Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis. | Blood Cancer J | 2022 | 35961958 | PubTator, text mining | PubMed |
| Increased Apoptotic Activity in Low-Risk Myelodysplastic Syndrome. | J Clin Med | 2022 | 35956220 | PubTator, text mining | PubMed |
| Histopathology and Molecular Genetics in Systemic Mastocytosis: Implications for Clinical Management. | Int J Mol Sci | 2022 | 35955907 | PubTator, text mining | PubMed |
| Pathogenic Roles of RNA-Binding Proteins in Sarcomas. | Cancers (Basel) | 2022 | 35954475 | PubTator, text mining | PubMed |
| Combined Systemic Drug Treatment with Proton Therapy: Investigations on Patient-Derived Organoids. | Cancers (Basel) | 2022 | 35954444 | PubTator, text mining | PubMed |
| Evaluation of a Patient With Non-Myoinvasive Uterine Serous Carcinoma Confined to a Polyp and Positive Peritoneal Washings With Somatic ARHGAP35 and KRAS Mutations. | Cureus | 2022 | 35949786 | PubTator, text mining | PubMed |
| TRABID targets DDB2 for deubiquitination to promote proliferation of hepatocellular carcinoma cells. | Biochem Biophys Res Commun | 2022 | 35944360 | PubTator, text mining | PubMed |
| Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates. | Cancer | 2022 | 35942592 | PubTator, text mining | PubMed |
| Unified classification and risk-stratification in Acute Myeloid Leukemia. | Nat Commun | 2022 | 35941135 | PubTator, text mining | PubMed |
| Durable response to ivosidenib in post-transplant relapse and leukemic transformation of myelodysplastic syndrome with new complex karyotype and IDH1 R132C mutation. | Leuk Lymphoma | 2022 | 35938721 | PubTator, text mining | PubMed |
| Abnormal CD13/HLA-DR Expression Pattern on Myeloblasts Predicts Development of Myeloid Neoplasia in Patients With Clonal Cytopenia of Undetermined Significance. | Am J Clin Pathol | 2022 | 35938646 | PubTator, text mining | PubMed |
| Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial. | J Intern Med | 2022 | 35934913 | PubTator, text mining | PubMed |
| Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission. | Haematologica | 2022 | 35924576 | PubTator, text mining | PubMed |
| Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. | Leukemia | 2022 | 35922444 | PubTator, text mining | PubMed |
| Mapping subcellular localizations of unannotated microproteins and alternative proteins with MicroID. | Mol Cell | 2022 | 35905735 | PubTator, text mining | PubMed |
| Boosting Antitumor Immunity with an Expanded Neoepitope Landscape. | Cancer Res | 2022 | 35904353 | PubTator, text mining | PubMed |
| ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. | Leukemia | 2022 | 35902731 | PubTator, text mining | PubMed |
| Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. | JAMA Oncol | 2022 | 35900726 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7307/papers?page=43